| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 62,786 | 48,985 | ||
| Marketable securities | 14,389 | 14,195 | ||
| Prepaid expenses and other current assets | 1,759 | 3,536 | ||
| Total current assets | 78,934 | 66,716 | ||
| Property and equipment, net | 516 | 530 | ||
| Right-of-use asset - operating lease | 1,074 | 1,206 | ||
| Other assets | 405 | 472 | ||
| Total assets | 80,929 | 68,924 | ||
| Accounts payable | 1,831 | 486 | ||
| Accrued expenses | 8,417 | 6,582 | ||
| Note payable | 658 | 933 | ||
| Deferred revenue - current portion | 2,141 | 2,514 | ||
| Operating lease obligation - current portion | 597 | 640 | ||
| Total current liabilities | 13,644 | 11,155 | ||
| Deferred revenue - non-current portion | 336 | 221 | ||
| Operating lease obligation - non-current portion | 610 | 783 | ||
| Total liabilities | 14,590 | 12,159 | ||
| Common stock, 0.001 par value 325,000,000 shares authorized at september30, 2025 and march31, 2025 38,895,568 and 29,001,481 shares issued at september30, 2025 and march31, 2025, respectively | 39 | 29 | ||
| Additional paid-in capital | 512,398 | 483,430 | ||
| Treasury stock, at cost, 4,522 shares of common stock held at september30, 2025 and march31, 2025 | 3,968 | 3,968 | ||
| Accumulated other comprehensive income | 14 | 1 | ||
| Accumulated deficit | -442,144 | -422,727 | ||
| Total stockholders equity | 66,339 | 56,765 | ||
| Total liabilities and stockholders equity | 80,929 | 68,924 | ||
Vistagen Therapeutics, Inc. (VTGN)
Vistagen Therapeutics, Inc. (VTGN)